Therapeutic efficacy of TACE 125I seed implantation and its combination with intra-tumor injection of cisplatin for the treatment of hepatocellular carcinoma
Background: This study aimed to compare the therapeutic efficacy of transcatheter arterial chemoembolization (TACE) combined with either 125I seed implantation or 125I seed implantation and intra-tumor injection of cisplatin in treating hepatocellular carcinoma (HCC). Methods: A total of 100 patient...
Gespeichert in:
| Veröffentlicht in: | Indian journal of cancer 2021-01, Vol.58 (1), p.57-61 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 61 |
|---|---|
| container_issue | 1 |
| container_start_page | 57 |
| container_title | Indian journal of cancer |
| container_volume | 58 |
| creator | Song, Zhaomin Guo, Xiaoqing Yin, Chenghui Wang, Yongzheng |
| description | Background: This study aimed to compare the therapeutic efficacy of transcatheter arterial chemoembolization (TACE) combined with either 125I seed implantation or 125I seed implantation and intra-tumor injection of cisplatin in treating hepatocellular carcinoma (HCC).
Methods: A total of 100 patients with HCC were analyzed. The control group (n = 50) received TACE combined with 125I seed implantation therapy. The therapy group (n = 50) was treated with an intra-tumor injection of cisplatin along with TACE and 125I seed implantation therapy. After treatment, routine blood, liver and kidney function, tumor volume, T lymphocyte subset count (CD3, CD4, and CD8), implanted metastases, and survival were studied.
Results: The tumor volume decreased by 27.4% on average in the control group, and by 38.6% in the therapy group. Alpha fetoprotein (AFP) level decreased in all cases, and it was significantly lower in the therapy group than in the control group. Remote metastasis was observed in both groups (7 in the control group and 3 in the therapy group). No significant difference in routine blood, liver and kidney function, and T-lymphocyte subset counts were found between the two groups. Eight patients died of metastases in the control group and 2 in the therapy group at 1-year follow-up (P < 0.05).
Conclusion: TACE combined with either 125I seed implantation or 125I seed implantation and intra-tumor injection of cisplatin was effective for the treatment of HCC. Of the 2 combination therapies, TACE combined with 125I seed implantation and intra-tumor injection of cisplatin was more effective for the treatment of HCC. |
| doi_str_mv | 10.4103/ijc.IJC_635_18 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_journals_2532571157</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A656638949</galeid><sourcerecordid>A656638949</sourcerecordid><originalsourceid>FETCH-LOGICAL-g338u-6bcacbbdf8102c76d411ede92502aa5cbb4b72109fac38f12ceca1fa19956f173</originalsourceid><addsrcrecordid>eNptkktrGzEUhYfSQN2k264Fhe7G1WM0j1UxJm1dAt04kJ3QaK48cjSSK2kw-TH9r5XrliZgtJA457tX0uUUxXuClxXB7JPZq-Xm-1rUjAvSvioWpOvasmqa6nWxwJh0Jcfdw5vibYx7jCmjVbsofm1HCPIAczIKgdZGSfWEvEbb1foWEco3KAIMyEwHK12SyXiHpMtCikj5qTfurB1NGpFxKcgyzZMP-bwH9cfK3ZSJuT4Zh3S20ggoBZBpApdO9ggHmbwCa2crA1IyKOP8JG-KKy1thHd_9-vi_svtdv2tvPvxdbNe3ZU7xtq5rPv86r4fdEswVU09VITAAB3lmErJs1X1DSW401KxVhOqQEmiZR4QrzVp2HXx4dz3EPzPGWISez8Hl68UlDPKG0L4M2onLQjjtM-_VZOJSqxqXtes7aouU-UFagcuz9l6B9pk-QW_vMDnNcBk1MWCj88KRpA2jdHb-TTr-BL8fAaP3iYI8dHORwhiguHR-aMgWJxyI3JuxP_cCN6If5lgvwFOSL03</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2532571157</pqid></control><display><type>article</type><title>Therapeutic efficacy of TACE 125I seed implantation and its combination with intra-tumor injection of cisplatin for the treatment of hepatocellular carcinoma</title><source>Medknow Open Access Medical Journals</source><source>Bioline International</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Song, Zhaomin ; Guo, Xiaoqing ; Yin, Chenghui ; Wang, Yongzheng</creator><creatorcontrib>Song, Zhaomin ; Guo, Xiaoqing ; Yin, Chenghui ; Wang, Yongzheng</creatorcontrib><description>Background: This study aimed to compare the therapeutic efficacy of transcatheter arterial chemoembolization (TACE) combined with either 125I seed implantation or 125I seed implantation and intra-tumor injection of cisplatin in treating hepatocellular carcinoma (HCC).
Methods: A total of 100 patients with HCC were analyzed. The control group (n = 50) received TACE combined with 125I seed implantation therapy. The therapy group (n = 50) was treated with an intra-tumor injection of cisplatin along with TACE and 125I seed implantation therapy. After treatment, routine blood, liver and kidney function, tumor volume, T lymphocyte subset count (CD3, CD4, and CD8), implanted metastases, and survival were studied.
Results: The tumor volume decreased by 27.4% on average in the control group, and by 38.6% in the therapy group. Alpha fetoprotein (AFP) level decreased in all cases, and it was significantly lower in the therapy group than in the control group. Remote metastasis was observed in both groups (7 in the control group and 3 in the therapy group). No significant difference in routine blood, liver and kidney function, and T-lymphocyte subset counts were found between the two groups. Eight patients died of metastases in the control group and 2 in the therapy group at 1-year follow-up (P < 0.05).
Conclusion: TACE combined with either 125I seed implantation or 125I seed implantation and intra-tumor injection of cisplatin was effective for the treatment of HCC. Of the 2 combination therapies, TACE combined with 125I seed implantation and intra-tumor injection of cisplatin was more effective for the treatment of HCC.</description><identifier>ISSN: 0019-509X</identifier><identifier>EISSN: 1998-4774</identifier><identifier>DOI: 10.4103/ijc.IJC_635_18</identifier><language>eng</language><publisher>Mumbai: Wolters Kluwer India Pvt. Ltd</publisher><subject>Antimitotic agents ; Antineoplastic agents ; Cancer ; Care and treatment ; Chemotherapy ; Health aspects ; Hepatoma ; Liver cancer ; Metastasis</subject><ispartof>Indian journal of cancer, 2021-01, Vol.58 (1), p.57-61</ispartof><rights>COPYRIGHT 2021 Medknow Publications and Media Pvt. Ltd.</rights><rights>2021. This article is published under (http://creativecommons.org/licenses/by-nc-sa/3.0/) (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27435,27901,27902</link.rule.ids></links><search><creatorcontrib>Song, Zhaomin</creatorcontrib><creatorcontrib>Guo, Xiaoqing</creatorcontrib><creatorcontrib>Yin, Chenghui</creatorcontrib><creatorcontrib>Wang, Yongzheng</creatorcontrib><title>Therapeutic efficacy of TACE 125I seed implantation and its combination with intra-tumor injection of cisplatin for the treatment of hepatocellular carcinoma</title><title>Indian journal of cancer</title><description>Background: This study aimed to compare the therapeutic efficacy of transcatheter arterial chemoembolization (TACE) combined with either 125I seed implantation or 125I seed implantation and intra-tumor injection of cisplatin in treating hepatocellular carcinoma (HCC).
Methods: A total of 100 patients with HCC were analyzed. The control group (n = 50) received TACE combined with 125I seed implantation therapy. The therapy group (n = 50) was treated with an intra-tumor injection of cisplatin along with TACE and 125I seed implantation therapy. After treatment, routine blood, liver and kidney function, tumor volume, T lymphocyte subset count (CD3, CD4, and CD8), implanted metastases, and survival were studied.
Results: The tumor volume decreased by 27.4% on average in the control group, and by 38.6% in the therapy group. Alpha fetoprotein (AFP) level decreased in all cases, and it was significantly lower in the therapy group than in the control group. Remote metastasis was observed in both groups (7 in the control group and 3 in the therapy group). No significant difference in routine blood, liver and kidney function, and T-lymphocyte subset counts were found between the two groups. Eight patients died of metastases in the control group and 2 in the therapy group at 1-year follow-up (P < 0.05).
Conclusion: TACE combined with either 125I seed implantation or 125I seed implantation and intra-tumor injection of cisplatin was effective for the treatment of HCC. Of the 2 combination therapies, TACE combined with 125I seed implantation and intra-tumor injection of cisplatin was more effective for the treatment of HCC.</description><subject>Antimitotic agents</subject><subject>Antineoplastic agents</subject><subject>Cancer</subject><subject>Care and treatment</subject><subject>Chemotherapy</subject><subject>Health aspects</subject><subject>Hepatoma</subject><subject>Liver cancer</subject><subject>Metastasis</subject><issn>0019-509X</issn><issn>1998-4774</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNptkktrGzEUhYfSQN2k264Fhe7G1WM0j1UxJm1dAt04kJ3QaK48cjSSK2kw-TH9r5XrliZgtJA457tX0uUUxXuClxXB7JPZq-Xm-1rUjAvSvioWpOvasmqa6nWxwJh0Jcfdw5vibYx7jCmjVbsofm1HCPIAczIKgdZGSfWEvEbb1foWEco3KAIMyEwHK12SyXiHpMtCikj5qTfurB1NGpFxKcgyzZMP-bwH9cfK3ZSJuT4Zh3S20ggoBZBpApdO9ggHmbwCa2crA1IyKOP8JG-KKy1thHd_9-vi_svtdv2tvPvxdbNe3ZU7xtq5rPv86r4fdEswVU09VITAAB3lmErJs1X1DSW401KxVhOqQEmiZR4QrzVp2HXx4dz3EPzPGWISez8Hl68UlDPKG0L4M2onLQjjtM-_VZOJSqxqXtes7aouU-UFagcuz9l6B9pk-QW_vMDnNcBk1MWCj88KRpA2jdHb-TTr-BL8fAaP3iYI8dHORwhiguHR-aMgWJxyI3JuxP_cCN6If5lgvwFOSL03</recordid><startdate>20210101</startdate><enddate>20210101</enddate><creator>Song, Zhaomin</creator><creator>Guo, Xiaoqing</creator><creator>Yin, Chenghui</creator><creator>Wang, Yongzheng</creator><general>Wolters Kluwer India Pvt. Ltd</general><general>Medknow Publications and Media Pvt. Ltd</general><general>Medknow Publications & Media Pvt. Ltd</general><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>20210101</creationdate><title>Therapeutic efficacy of TACE 125I seed implantation and its combination with intra-tumor injection of cisplatin for the treatment of hepatocellular carcinoma</title><author>Song, Zhaomin ; Guo, Xiaoqing ; Yin, Chenghui ; Wang, Yongzheng</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-g338u-6bcacbbdf8102c76d411ede92502aa5cbb4b72109fac38f12ceca1fa19956f173</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Antimitotic agents</topic><topic>Antineoplastic agents</topic><topic>Cancer</topic><topic>Care and treatment</topic><topic>Chemotherapy</topic><topic>Health aspects</topic><topic>Hepatoma</topic><topic>Liver cancer</topic><topic>Metastasis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Song, Zhaomin</creatorcontrib><creatorcontrib>Guo, Xiaoqing</creatorcontrib><creatorcontrib>Yin, Chenghui</creatorcontrib><creatorcontrib>Wang, Yongzheng</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Indian journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Song, Zhaomin</au><au>Guo, Xiaoqing</au><au>Yin, Chenghui</au><au>Wang, Yongzheng</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Therapeutic efficacy of TACE 125I seed implantation and its combination with intra-tumor injection of cisplatin for the treatment of hepatocellular carcinoma</atitle><jtitle>Indian journal of cancer</jtitle><date>2021-01-01</date><risdate>2021</risdate><volume>58</volume><issue>1</issue><spage>57</spage><epage>61</epage><pages>57-61</pages><issn>0019-509X</issn><eissn>1998-4774</eissn><abstract>Background: This study aimed to compare the therapeutic efficacy of transcatheter arterial chemoembolization (TACE) combined with either 125I seed implantation or 125I seed implantation and intra-tumor injection of cisplatin in treating hepatocellular carcinoma (HCC).
Methods: A total of 100 patients with HCC were analyzed. The control group (n = 50) received TACE combined with 125I seed implantation therapy. The therapy group (n = 50) was treated with an intra-tumor injection of cisplatin along with TACE and 125I seed implantation therapy. After treatment, routine blood, liver and kidney function, tumor volume, T lymphocyte subset count (CD3, CD4, and CD8), implanted metastases, and survival were studied.
Results: The tumor volume decreased by 27.4% on average in the control group, and by 38.6% in the therapy group. Alpha fetoprotein (AFP) level decreased in all cases, and it was significantly lower in the therapy group than in the control group. Remote metastasis was observed in both groups (7 in the control group and 3 in the therapy group). No significant difference in routine blood, liver and kidney function, and T-lymphocyte subset counts were found between the two groups. Eight patients died of metastases in the control group and 2 in the therapy group at 1-year follow-up (P < 0.05).
Conclusion: TACE combined with either 125I seed implantation or 125I seed implantation and intra-tumor injection of cisplatin was effective for the treatment of HCC. Of the 2 combination therapies, TACE combined with 125I seed implantation and intra-tumor injection of cisplatin was more effective for the treatment of HCC.</abstract><cop>Mumbai</cop><pub>Wolters Kluwer India Pvt. Ltd</pub><doi>10.4103/ijc.IJC_635_18</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0019-509X |
| ispartof | Indian journal of cancer, 2021-01, Vol.58 (1), p.57-61 |
| issn | 0019-509X 1998-4774 |
| language | eng |
| recordid | cdi_proquest_journals_2532571157 |
| source | Medknow Open Access Medical Journals; Bioline International; EZB-FREE-00999 freely available EZB journals |
| subjects | Antimitotic agents Antineoplastic agents Cancer Care and treatment Chemotherapy Health aspects Hepatoma Liver cancer Metastasis |
| title | Therapeutic efficacy of TACE 125I seed implantation and its combination with intra-tumor injection of cisplatin for the treatment of hepatocellular carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T22%3A51%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Therapeutic%20efficacy%20of%20TACE%20125I%20seed%20implantation%20and%20its%20combination%20with%20intra-tumor%20injection%20of%20cisplatin%20for%20the%20treatment%20of%20hepatocellular%20carcinoma&rft.jtitle=Indian%20journal%20of%20cancer&rft.au=Song,%20Zhaomin&rft.date=2021-01-01&rft.volume=58&rft.issue=1&rft.spage=57&rft.epage=61&rft.pages=57-61&rft.issn=0019-509X&rft.eissn=1998-4774&rft_id=info:doi/10.4103/ijc.IJC_635_18&rft_dat=%3Cgale_proqu%3EA656638949%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2532571157&rft_id=info:pmid/&rft_galeid=A656638949&rfr_iscdi=true |